Biosimilar White Papers

1. Strategies For Upstream Intensification 8/14/2020

   Upstream intensification is one strategy that will enable the Facility Of The Future by significantly driving down costs through an increase in volumetric productivity. Read the white paper to learn more!

2. Guidelines For A High Cell Density Cryopreservation Process 8/11/2021

   A discussion on the integration of high cell density cryopreservation in the seed train andkey considerations for developing a cryopreservation process including choice of cryoprotectant and freezing techniques.

3. Accelerate CHO Cell Characterization With The Blazar™ Rodent Panel 2/24/2021

   The Blazar Rodent Panel allows biopharma to move away from traditional in vivo antibody production assays when characterizing cell banks of rodent origin used in the production of biologicals.

4. Turnkey Solutions To Improve Cell Culture Performance 2/16/2022

   This white paper describes the benefits of a one-step and neutral pH feed optimization strategy, as well as the potential application of chemically defined hydrolysates.

5. Cell Therapy Scale-Up Strategies For Commercial Success 9/30/2020

   This article discusses options for cell therapy process development and validation that minimize risks through quality control (QC), optimization, scaling, closing, automation, and assay development.

6. 8 mm Needle – Improving Subcutaneous Chronic Drug Delivery 7/21/2020

   Reducing needle length can improve the risk profile of subcutaneous injections and can make injecting viscous formulations easier and quicker.

7. Secure The Cell Therapy Supply Chain From Bench To Bedside 10/4/2021

   While current approaches can manage the existing volume of cell therapy shipments, scaling these treatments up and out will increase pressure on cryogenic logistics networks. 

8. Meeting Diverse Biologic Pipeline Development Challenges 9/10/2020

   The biopharma manufacturing industry has been evolving at an unmatched pace. Understanding and managing diverse molecule challenges is key to reaching patients safely and efficiently.  

9. Leading The Edge Of Innovation Into Cell Culture Media Quality 12/16/2020

   In this white paper, we highlight the breadth of programs implemented across our organization to safeguard the quality of the cell culture media that are used in our customer processes.

10. CDMO Collaboration: Foundation For Sterile Injectable Product Success 6/1/2021

    Explore how a small or medium size biotech or pharma company eveloping sterile injectables can benefit from the experience and assistance provided by a CDMO.